Abstract:Sphingosine-1-phosphate (S1P) is a bioactive lipid metabolite that exerts its actions by engaging 5 G-protein-coupled receptors (S1PR1-S1PR5). S1P receptors are involved in several cellular and physiological events, including lymphocyte/hematopoietic cell trafficking. An S1P gradient (low in tissues, high in blood), maintained by synthetic and degradative enzymes, regulates lymphocyte trafficking. Because lymphocytes live long (which is critical for adaptive immunity) and recirculate thousands of times, the S1P-S1PR pathway is involved in the pathogenesis of immune-mediated diseases. The S1PR1 modulators lead to receptor internalization, subsequent ubiquitination, and proteasome degradation, which renders lymphocytes incapable of following the S1P gradient and prevents their access to inflammation sites. These drugs might also block lymphocyte egress from lymph nodes by inhibiting transendothelial migration. Targeting S1PRs as a therapeutic strategy was first employed for multiple sclerosis (MS), and four S1P modulators (fingolimod, siponimod, ozanimod, and ponesimod) are currently approved for its treatment. New S1PR modulators are under clinical development for MS, and their uses are being evaluated to treat other immune-mediated diseases, including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriasis. A clinical trial in patients with COVID-19 treated with ozanimod is ongoing. Ozanimod and etrasimod have shown promising results in IBD; while in phase 2 clinical trials, ponesimod has shown improvement in 77% of the patients with psoriasis. Cenerimod and amiselimod have been tested in SLE patients. Fingolimod, etrasimod, and IMMH001 have shown efficacy in RA preclinical studies. Concerns relating to S1PR modulators are leukopenia, anemia, transaminase elevation, macular edema, teratogenicity, pulmonary disorders, infections, and cardiovascular events. Furthermore, S1PR modulators exhibit different pharmacokinetics; a well-established first-dose event associated with S1PR modulators can be mitigated by gradual up-titration. In conclusion, S1P modulators represent a novel and promising therapeutic strategy for immune-mediated diseases.

Sphingosine 1-phosphate: Lipid signaling in pathology and therapy

Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.

Sphingosine 1-phosphate and inflammation.

Sphingosine-1-phosphate: a Potential Therapeutic Target for Rheumatoid Arthritis

Sphingosine 1-Phosphate as Essential Signaling Molecule in Inflammatory Skin Diseases

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis

Sphingosine 1-phosphate, a key mediator of the cytokine network: juxtacrine signaling.

Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases

Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases

Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects

Regulation of cellular and systemic sphingolipid homeostasis

Sphingolipids and their metabolism in physiology and disease

Deciphering the role of sphingosine 1‐phosphate in central nervous system myelination and repair

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation

Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases

Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology

How do sphingosine-1-phosphate affect immune cells to resolve inflammation?

Role of Sphingosine-1-Phosphate Signaling Pathway in Pancreatic Diseases

Sphingosine 1-phosphate in blood: function, metabolism, and fate

Modulation of protein kinase C and diverse cell functions by sphingosine--a pharmacologically interesting compound linking sphingolipids and signal transduction

Emerging roles of sphingosylphosphorylcholine in modulating cardiovascular functions and diseases